Tag: microbiome
-
Apersy’s 1st anniversary
I started with the vision to create independent market access services that can support health tech companies through the challenges of precision medicine, complex treatment regimens and care approaches that blur the boundaries between device, pharmaceuticals and digital.
-
Apersy at the 11th Microbiome & Probiotic R&D & Business Collaboration Forum: Europe, Rotterdam, 23-24 May 2023
Apersy puts focus on market access preparedness at the 11th Microbiome & Probiotic R&D & Business Collaboration Forum: Europe (Rotterdam, 23-24 May 2023).
-
Microbiome-targeting medicines: Commercial launch is moving centre stage
While Europe still lags behind in terms of microbiome medicines approvals, in the UK, we have seen the first Health Technology Assessment (HTA) for microbiota medicines. Let’s have a closer look…
-
February 2023 Monthly Reading List
Selected reads from recent press or publications in the disruptive value, commercial and reimbursement space.
-
December 2022 Market Access news recap
The monthy 3 minutes of selected bits of news: 62 seconds on DiPAs – digital care and nursing applications are launching in Germany Microbiome product Rebyota is now approved in the US – we are keenly watching out for access, uptake and reimbursement learnings… AIFA reimbursement committees merge Germany rare disease medicine Brineura to recevie…
-
August & September 2022 Market Access news recap
After the summer break, let’s quickly catch-up with selected August and September news from the access and reimbursement sphere….